Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -2.08%33 EV-to-FCF is -27.72 as of Jul. 14, 2026. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 335 Biotechnology companies, Island Pharmaceuticals ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Island Pharmaceuticals's Enterprise Value is A$125.22 Mil.
Island Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.52 Mil. Therefore, Island Pharmaceuticals's EV-to-FCF for today is -27.72.
The historical rank and industry rank for Island Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ASX:ILA'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.17 Med: -6.77 Max: -1.46
Current: -31.17
During the past 5 years, the highest EV-to-FCF of Island Pharmaceuticals was -1.46. The lowest was -31.17. And the median was -6.77.
ASX:ILA's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs ASX:ILA: -31.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Island Pharmaceuticals (ASX:ILA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Island Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Island Pharmaceuticals's share price for today is A$0.47.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Island Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.031.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Island Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's EV-to-FCF falls into.
Island Pharmaceuticals's current Enterprise Value is A$125.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Island Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Island Pharmaceuticals (ASX:ILA) has a EV-to-FCF of -27.72 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Island Pharmaceuticals and its competitors. According to the industry distribution chart, Island Pharmaceuticals ranks #999999 out of 335 companies in the Biotechnology industry.
Is Island Pharmaceuticals' EV-to-FCF too high?
Island Pharmaceuticals' current EV-to-FCF is -27.72. Based on the distribution chart, Island Pharmaceuticals ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #999999 out of 335 companies for EV-to-FCF. This places Island Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current EV-to-FCF is -27.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current EV-to-FCF of -27.72. The current EV-to-FCF is -27.72. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current EV-to-FCF is -27.72 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score
Get the complete analysis for ASX:ILA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
